Results of an early-stage study suggested that nearly two-thirds of patients with late stage non-small-cell lung cancer who received the experimental drug crizotinib were alive after two years.
In the study, 82 previously-treated NSCLC patients with anaplastic lymphoma kinase (ALK) in their lung tumors were given crizotinib.
The results showed that 77 percent of patients were alive after on year and 64 percent were alive after two years. This compared favorably with historical data when only 46 percent of patients were alive after one year and only 9 percent were alive after two years.
Earlier this week, the company (Pfizer), which made this drug, indicated that the company has filed marketing applications in theUSandJapan. If approved, this drug will be indicated for the treatment of patients with advanced NSCLC whose tumors are ALK-positive.
Please visit us at healthreason.com for more health related articles.